1. Home
  2. XRTX vs SPHL Comparison

XRTX vs SPHL Comparison

Compare XRTX & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XRTX
  • SPHL
  • Stock Information
  • Founded
  • XRTX 2011
  • SPHL 2002
  • Country
  • XRTX Canada
  • SPHL Singapore
  • Employees
  • XRTX N/A
  • SPHL N/A
  • Industry
  • XRTX Pharmaceuticals and Biotechnology
  • SPHL Homebuilding
  • Sector
  • XRTX Health Care
  • SPHL Consumer Discretionary
  • Exchange
  • XRTX Nasdaq
  • SPHL Nasdaq
  • Market Cap
  • XRTX 4.5M
  • SPHL 4.9M
  • IPO Year
  • XRTX N/A
  • SPHL 2024
  • Fundamental
  • Price
  • XRTX $0.90
  • SPHL $0.65
  • Analyst Decision
  • XRTX
  • SPHL
  • Analyst Count
  • XRTX 0
  • SPHL 0
  • Target Price
  • XRTX N/A
  • SPHL N/A
  • AVG Volume (30 Days)
  • XRTX 46.7K
  • SPHL 3.4M
  • Earning Date
  • XRTX 11-14-2025
  • SPHL 10-28-2025
  • Dividend Yield
  • XRTX N/A
  • SPHL N/A
  • EPS Growth
  • XRTX N/A
  • SPHL N/A
  • EPS
  • XRTX N/A
  • SPHL N/A
  • Revenue
  • XRTX N/A
  • SPHL $5,956,226.00
  • Revenue This Year
  • XRTX N/A
  • SPHL N/A
  • Revenue Next Year
  • XRTX N/A
  • SPHL N/A
  • P/E Ratio
  • XRTX N/A
  • SPHL N/A
  • Revenue Growth
  • XRTX N/A
  • SPHL N/A
  • 52 Week Low
  • XRTX $0.66
  • SPHL $0.35
  • 52 Week High
  • XRTX $2.51
  • SPHL $7.80
  • Technical
  • Relative Strength Index (RSI)
  • XRTX 59.28
  • SPHL 63.26
  • Support Level
  • XRTX $0.79
  • SPHL $0.52
  • Resistance Level
  • XRTX $0.91
  • SPHL $0.85
  • Average True Range (ATR)
  • XRTX 0.03
  • SPHL 0.09
  • MACD
  • XRTX 0.01
  • SPHL 0.01
  • Stochastic Oscillator
  • XRTX 92.67
  • SPHL 59.30

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.

Share on Social Networks: